3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
102
Thyroid Neoplasms
40
Thyroid Cancer, Papillary
36
Carcinoid Tumor
32
Neoplasms
28
Multiple Endocrine Neoplasia Type 1
22
Adenocarcinoma, Follicular
22
Thyroid Carcinoma, Anaplastic
21
Neoplasm Metastasis
21
Pituitary Neoplasms
20
Carcinoma, Neuroendocrine
20
Pheochromocytoma
19
Carcinoma, Medullary
19
Paraganglioma
17
Carcinoma, Non-Small-Cell Lung
17
Somatostatinoma
16
Adrenocortical Carcinoma
16
Pancreatic Neoplasms
14
Carcinoma, Islet Cell
14
Insulinoma
12
Glucagonoma
12
Adenoma, Islet Cell
12
Gastrinoma
11
Colorectal Neoplasms
11
Breast Neoplasms
11
Sarcoma
10
Melanoma
10
Gastro-enteropancreatic neuroendocrine tumor
10
Carcinoma, Renal Cell
10
Pituitary ACTH Hypersecretion
9
Interventions
Octreotide
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Malignant Carcinoid Syndrome
×
Endocrine
×
Clear all
NCT00412061
2014-11-21
RADIANT-2
Novartis
Phase 3
Completed
429 enrolled
13 charts